VETERINARY DERMATOLOGY DRUGS MARKET ANALYSIS

Market News

Veterinary Dermatology Drugs Market Recent Developments

New product launches

1. Cytopoint: Zoetis launched Cytopoint, a monoclonal antibody therapy for the treatment of atopic dermatitis in dogs, in 2016. It offers a longer duration of effect than traditional therapies and reduces the need for frequent administration.
2. Galliprant: Elanco launched Galliprant, a novel non-steroidal anti-inflammatory drug for the treatment of pain and inflammation associated with osteoarthritis in dogs, in 2016. It has a targeted mechanism of action and is well-tolerated by dogs.
3. Osurnia: Elanco also launched Osurnia, a topical treatment for otitis externa (ear infections) in dogs, in 2016. It offers a single-dose administration and a favorable safety profile.
4. Atopica: Elanco's Atopica is an oral medication for the treatment of atopic dermatitis in dogs. It is an immunosuppressant that targets the immune system response that causes the disease.
5. Sileo: Zoetis launched Sileo, an oral medication for the treatment of noise aversion in dogs, in 2016. It reduces anxiety and fear associated with loud noises such as thunderstorms and fireworks.

Acquisition and partnerships

1. Elanco's acquisition of Bayer Animal Health: In 2020, Elanco completed its acquisition of Bayer Animal Health, expanding its portfolio of animal health products, including dermatology drugs for pets.
2. Zoetis' partnership with Kindred Biosciences: In 2020, Zoetis entered into a partnership with Kindred Biosciences to develop and market a monoclonal antibody therapy for the treatment of atopic dermatitis in dogs.
3. Zoetis' partnership with Ethos Veterinary Health: In 2020, Zoetis announced a partnership with Ethos Veterinary Health to improve access to dermatology care for pets across the United States, by providing advanced dermatology services and innovative treatments.
4. Dechra's partnership with MediBeacon: In 2020, Dechra announced a partnership with MediBeacon to develop a non-invasive diagnostic tool for the assessment of skin health in pets, enabling earlier detection and treatment of skin diseases.
5. Vetoquinol's acquisition of Clarion Biociências: In 2021, Vetoquinol announced its acquisition of Clarion Biociências, a Brazilian veterinary pharmaceutical company, to expand its presence in the Latin American market, including dermatology products.